HOME >> BIOLOGY >> NEWS
Hydroxyurea therapy improves survival in most severely affected sickle cell patients

Sickle cell anemia patients who took the drug hydroxyurea over a 9-year period experienced a 40 percent reduction in deaths, according to the first study to evaluate whether the treatment prolongs life, announced the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

The study of 299 adult sickle cell patients with moderate to severe forms of the disease, found that improved survival was related to the benefits associated with hydroxyurea treatment an increase in fetal hemoglobin and reduced episodes of severe pain "crises" and chest syndrome, a pneumonia-like illness. The results were published in the April 2 issue of The Journal of the American Medical Association.

Previous research has shown the benefits of hydroxyurea in reducing the symptoms of the most severely affected sickle cell patients those who have 3 or more painful crises each year.

"The current study shows that hydroxyurea can improve the survival of the sickest patients. Now there is new hope for these patients, who typically die 10 to 15 years earlier than patients with milder cases," said NHLBI Director Claude Lenfant, M.D.

Patients in the new study were originally participants in the NHLBI's Multicenter Study of Hydroxyurea (MSH) in Sickle Cell Anemia. That clinical trial was designed to test whether hydroxyurea reduced symptoms of the disease compared to placebo in patients who had 3 or more crises per year. Patients were randomly assigned to hydroxyurea or placebo and the study was "double-blinded" indicating neither patients nor physicians knew who was taking the drug.

Over 2 1/ 2 years, the drug resulted in an almost 50 percent reduction in the number of painful crises and episodes of chest syndrome. Patients on hydroxyurea also required about 50 percent fewer transfusions and hospitalizations. These results, reported in 1995, were reviewed by the Food and Drug Administration (FDA) and hydroxyurea became the first FDA
'"/>

Contact: NHLBI Communications Office
301-496-4236
NIH/National Heart, Lung, and Blood Institute
1-Apr-2003


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/5/2018)... (PRWEB) , ... October 05, 2018 , ... ... North America, Inc. (AHN), is announcing a 10% price increase across all markets ... produces amino acids — the building blocks of protein — for the parenteral ...
(Date:10/5/2018)... ... October 04, 2018 , ... ... and Monroe County Economic Development Corporation (EDC), has been awarded $680,000 under ... Agriculture (NIFA) Non-Land Grant College of Agriculture (NLGCA) Capacity-Building grants program. ...
(Date:10/5/2018)... LINDA, Calif. (PRWEB) , ... October 04, 2018 , ... ... results of some of the tests such as cardiac troponin has serious clinical complications. ... population, although the exact prevalence is still unknown. , High dose of biotin ...
Breaking Biology News(10 mins):
(Date:10/13/2018)... ... 12, 2018 , ... The Laser Institute of America ... its 50th birthday in New York’s Times Square today, ahead of its 37th ... , In celebration of its 50 years, LIA showed thanks to the support ...
(Date:10/5/2018)... ... October 04, 2018 , ... ... genomics, along with Duke University, announced today at IDWeek™ 2018 the positive results ... detects pathogen DNA in plasma, accurately identified causative pathogens in patients with infective ...
(Date:10/2/2018)... Ohio (PRWEB) , ... October 02, 2018 , ... ... announced, and Locus Bio-Energy Solutions™, LLC’s (Locus Bio-Energy) AssurEOR product line was chosen ... World Oil and Gulf Energy Information, honor leading innovations in upstream oil applications ...
(Date:9/28/2018)... YORBA LINDA, Calif. (PRWEB) , ... September 28, ... ... educational and interactive virtual events for tech innovators, engineers, and scientists from around ... Peru studying at the National University of San Marcos, as the winner of ...
Breaking Biology Technology:
Cached News: